Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 7567-63-7 | MDL No. : | MFCD00068621 |
Formula : | C12H6 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | ZDRMMTYSQSIGRY-UHFFFAOYSA-N |
M.W : | 150.18 | Pubchem ID : | 139048 |
Synonyms : |
|
Num. heavy atoms : | 12 |
Num. arom. heavy atoms : | 6 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 0 |
Num. H-bond acceptors : | 0.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 50.25 |
TPSA : | 0.0 Ų |
GI absorption : | Low |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.33 cm/s |
Log Po/w (iLOGP) : | 2.86 |
Log Po/w (XLOGP3) : | 2.66 |
Log Po/w (WLOGP) : | 1.87 |
Log Po/w (MLOGP) : | 4.79 |
Log Po/w (SILICOS-IT) : | 3.79 |
Consensus Log Po/w : | 3.19 |
Lipinski : | 1.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 2.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.82 |
Solubility : | 0.229 mg/ml ; 0.00152 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.31 |
Solubility : | 0.733 mg/ml ; 0.00488 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -2.63 |
Solubility : | 0.354 mg/ml ; 0.00236 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.94 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H319 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
87% | Stage #1: With caesium carbonate In methanol for 16 h; Stage #2: With ammonium chloride In dichloromethane; water |
(9) 1,3,5-trisethynyl-benzene. To a flame-dried flask under argon was added (8) (2.39 mmol, 1 eq), cesium carbonate (4.78 mmol, 2 eq), and methanol (10 mL). The reaction was stirred 16 hours. The solution went from opaque to translucent upon completion. The methanol was removed in vacuo and the solid was partitioned between water and methylene chloride. The water layer was extracted with methylene chloride (3*20 mL). The organic layer was washed with aqueous ammonium chloride (1.0 M, 2*20 mL), water (2*20 mL), and brine (2*20 mL). The organic layer was dried with sodium sulfate, filtered, and removed in vacuo. Product obtained as off-white soft crystals (2.09 mmol) in 87percent yield and had a melting point of 101-103° C. 1H NMR (400 MHz, CDCl3) δ 7.57 (s, 3H), 3.12 (s, 3H). 13C NMR (100 MHz, CDCl3) δ 135.6, 122.8, 81.6, 78.7. MS (CI+) m/z 151 [M]+. |
85% | With methanol; potassium carbonate In chloroform at 20℃; for 24 h; | A (1 g, 2.73 mmol) and K2CO3 (1.24 g, 8.99 mmol) were dissolved in 100 mL CHCl3/MeOH 3:2 and stirred at rt for 24 h. The solvent was removed on a rotary evaporator and the off-white solid was purified by silica gel column chromatography using dichloromethane/hexane 1:4 to give the product. Isolated yield: 350 mg. 1H NMR (CDCl3, 400 MHz): (ppm) 7.57 (s, 3H, H1), 3.11 (s, 3H, H2). 13C{1H} NMR (CDCl3, 100 MHz): (ppm) 136.12, 132.48, 123.38, 123.01, 83.51, 82.10, 70.59, 79.19. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
92% | With potassium hydroxide In toluene at 110℃; for 8 h; | General procedure: The procedure was modified following the Sonogashira coupling protocol. 1,3,5-Tribromobenzene (31.5 g, 100 mmol) was dissolved in dry triethylamine (250 mL) under an atmosphere of nitrogen. Copper(I) iodide (191 mg, 1.0 mmol), dichlorobis(dibenzonitrile)palladium(II) (192 mg, 0.5 mmol) were added to the stirred solution. After addition of 2-methyl-3-butyn-2-ol (12.6 g, 150 mmol) in drops, the reaction mixture was refluxed for 12 h under nitrogen atmosphere. At the room temperature, the formed precipitate of triethylamine hydroiodide was filtered off and washed with diethyl ether (3 * 50 mL). The combined filtrates were dried over anhydrous Na2SO4 and evaporated to have the crude product. Re-crystallization of this crude product in 20 mL of ethanol at -20 °C delivered white crystals of 2,2',2"-(benzene-1,3,5-triyltris(ethyne-2,1-diyl))tris(propan-2-ol) (3) (30.8 g, 95percent). The hydrolysis of compound 3 was carried out by treatment with KOH (19.2 g) and toluene 150 mL under stirring at 110 °C for 8 h. A standard work-up procedure involving evaporation of the organic solvent, extraction of the residue with diethyl ether, drying over Na2SO4, and removal of the solvent under reduced pressure yielded 1,3,5-triethynylbenzene 4) (13.0 g, 92percent) as colorless needle crystals. m.p. 95.4–96.0 °C; 1H NMR (300 MHz, CDCl3, ppm) δ 3.10 (s, 3H), 7.57 (s, 3H). |
52% | With potassium hydroxide In toluene for 5 h; Reflux | 2.2.2 1,3,5-Triethynylbenzene 2 [15]A solution of 3 (6.54 g, 19.62 mmol) in toluene (100 mL) was heated up to boiling.Powdered potassium hydroxide (3.30 g, 58.86 mmol) was added and the mixture refluxed for 5 h. After cooling down to room temperature, diethyl ether (50 mL) was added. The organic phase was washed with water (2 * 100 mL), dried (Na2SO4), and evaporated to give a dark brown solid which was purified by sublimation at 80 °C under vacuum yielding colorless needles of 2 (1.56 g, 52percent). Mp = 104 °C. 1H NMR (500.13 MHz, CDCl3): δH = 7.57 (s, Ar-H), 3.15 (s, C≡C-H).13C NMR (125.76 MHz, CDCl3): δC = 135.6, 122.9 (Ar-C), 81.6 (Ar-C≡C), 78.7 (Ar-C≡C). |